Clinical Test Expectation – GDF-8 (Myostatin HMP) – Human Subjects : Myostatin inhibitor. Massive gains in muscle growth. Healing of muscles and joints
Strength – 10MG per vial
Myostatin (GDF-8) is known as a potent inhibitor of muscle growth and development, and myostatin is also expressed early in the fracture healing process. The purpose of this study was to test the hypothesis that a new myostatin inhibitor, a recombinant myostatin propeptide, can enhance the repair and regeneration of both muscle and bone in cases of deep penetrant injury.
We used a fibula osteotomy model with associated damage to lateral compartment muscles (fibularis longus and brevis) in mice to test the hypothesis that blocking active myostatin with systemic injections of a recombinant myostatin propeptide would improve muscle and bone repair. Mice were assigned to two treatment groups after undergoing a fibula osteotomy: those receiving either vehicle (saline) or recombinant myostatin propeptide (20 mg/kg). Mice received one treatment on the day of surgery, another injection five days following surgery, and a third injection 10 days following surgery. Mice were euthanized 15 days following the osteotomy procedure. Bone repair was assessed using microCT and histological evaluation of the fracture callus. Muscle healing was assessed using Masson trichrome staining of the injury site, and image analysis used to quantify the degree of fibrosis and muscle regeneration.
Three propeptide injections over a period of 15 days increased body mass by 7% and increased muscle mass by almost 20% (P<.001). MicroCT analysis of the osteotomy site shows that by 15 days post-osteotomy, bony callus tissue was observed bridging the osteotomy gap in 80% of the propeptide- treated mice, but only 40% of the control (vehicle)-treated mice (P<.01). MicroCT quantification shows that bone volume of the fracture callus was increased by approximately 30% (P<.05) with propeptide treatment, and the increase in bone volume was accompanied by a significant increase in cartilage area (P=.01). Propeptide treatment significantly decreased the fraction of fibrous tissue in the wound site, and increased the fraction of muscle relative to fibrous tissue by 20% (P<.01).
Blocking myostatin signaling in the injured limb improves fracture healing and enhances muscle regeneration. These data suggest that myostatin inhibitors may be effective for improving wound repair in cases of orthopaedic trauma and extremity injury.
Dosing Details – GDF-8 (Myostatin HMP)
You inject 2.1ml water into the vial of GDF-8 from the water vial. 1 full syringe is 1ml. You then wait for the vial powder content to dissolve ON ITS OWN. DO NOT SHAKE THE VIAL TO MIX POWDER. Once dissolved and clear in colour you draw out 0.1 on the syringe each day in the morning and inject it into the muscle (Intra Muscular) at site of growth bilaterally (that is 0.05 into each side totaling 0.1) Directly into muscle. A vial should last 10 days.
How long will a vial last ?
A vial should last 10 days
Whatsapp our support team now for help with this item or others ! Click HERE to connect with us !